Nominated by YOU, meet your 2023 Leadership Award finalists for BioBuzz’s inaugural Annual Awards in Greater Philadelphia.
We are thrilled to announce the finalists for BioBuzz’s 2023 Annual Awards for Greater Philadelphia. Vote now to help us pick the winners. >
Here’s Where Verismo’s $17M pre-Series A Ranks Among Philly Biotech Venture Deals So Far In 2023
Greater Philadelphia Q4 2022 News Recap – December was a Pivotal Month for Cellicon Valley CompaniesPublished on :
Cellicon Valley companies closed out 2022 with a roar. Madrigal Pharmaceuticals announced a breakthrough in NASH that could result in the first-approved drug for that disease. Galera Therapeutics closed out December with plans to seek approval for its severe oral mucositis therapy.
The new lab space will allow the company to progress its pipeline with minimal delay and expenditure. The CIC Philadelphia-based lab space, which has undergone a recent expansion to double the number of available benches, will serve as one of Verismo’s in-house translational research and process development work. The work conducted at the site will support the ongoing activities for the SynKIR-110 clinical trial and future pipeline products including SynKIR-210 and SynKIR-310.
We’re excited to announce this year’s finalists for the third annual 2022 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
According to the recent Life Sciences Research Outlook & Cluster Rankings report from JLL, the Greater Philadelphia region has advanced four positions in the Life Sciences Cluster Composition Matrix, which measures how each market stacks up in terms of human and physical capital. The regional improvement was due to increased and steady funding supporting the specialization of cell and gene therapy research being conducted in the area, which comes as no surprise as these therapies continue to become increasingly important options in disease treatment.
The Phase 1 STAR-101 study will assess SynKIR-110 in patients with mesothelin expressing ovarian cancer, cholangiocarcinoma, and mesothelioma. Philadelphia-based Verismo, a spin-out of the University of Pennsylvania, is seeking to develop the experimental drug for the care of high, unmet needs in cancer. For each indication, the five-year survival rates are 49.7% for ovarian cancer, 30% for cholangiocarcinoma, and 10% for mesothelioma.
Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110, a KIR-CAR T-cell Immunotherapy CandidatePublished on :
Verismo Therapeutics, a Penn-spinout and the company behind the novel KIR-CAR platform technology for CAR T-cell therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to initiate its first-in-human Phase 1 clinical trial of SynKIR-110 in patients with mesothelin-expressing ovarian cancer, mesothelioma and cholangiocarcinoma.
Verismo Therapeutics, a recent University of Pennsylvania spin-out company behind the novel KIR-CAR platform technology for CAR T-cells, today announces that Penn and Verismo entered into a Sponsored Research Agreement (SRA). Under the SRA, Verismo is funding additional KIR-CAR T-cell focused preclinical research programs at Penn to advance new potential treatment options for solid tumor indications. The research funded under the SRA is expected to be conducted over four years, from 2021 to 2025, in the Penn laboratories of Michael C. Milone, MD, PhD, an associate professor of Pathology and Laboratory Medicine, and Donald L. Siegel, MD, PhD, a professor of Pathology and Laboratory Medicine.